- Home
- MTNB vs VRAX Comparison
MTNB vs VRAX Comparison
Compare MTNB & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTNB
- VRAX
- Stock Information
- Founded
- MTNB 2013
- VRAX 2013
- Country
- MTNB United States
- VRAX United Kingdom
- Employees
- MTNB N/A
- VRAX N/A
- Industry
- MTNB Biotechnology: Pharmaceutical Preparations
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MTNB Health Care
- VRAX Health Care
- Exchange
- MTNB Nasdaq
- VRAX Nasdaq
- Market Cap
- MTNB 5.2M
- VRAX 4.4M
- IPO Year
- MTNB N/A
- VRAX 2022
- Fundamental
- Price
- MTNB $0.93
- VRAX $0.99
- Analyst Decision
- MTNB Hold
- VRAX Strong Buy
- Analyst Count
- MTNB 1
- VRAX 1
- Target Price
- MTNB N/A
- VRAX $3.00
- AVG Volume (30 Days)
- MTNB 52.1K
- VRAX 149.4K
- Earning Date
- MTNB 08-13-2025
- VRAX 02-05-2025
- Dividend Yield
- MTNB N/A
- VRAX N/A
- EPS Growth
- MTNB N/A
- VRAX N/A
- EPS
- MTNB N/A
- VRAX N/A
- Revenue
- MTNB N/A
- VRAX $6,331.00
- Revenue This Year
- MTNB N/A
- VRAX $217,274.83
- Revenue Next Year
- MTNB N/A
- VRAX N/A
- P/E Ratio
- MTNB N/A
- VRAX N/A
- Revenue Growth
- MTNB N/A
- VRAX N/A
- 52 Week Low
- MTNB $0.47
- VRAX $0.74
- 52 Week High
- MTNB $8.75
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- MTNB 48.75
- VRAX 55.13
- Support Level
- MTNB $0.94
- VRAX $0.86
- Resistance Level
- MTNB $1.04
- VRAX $1.10
- Average True Range (ATR)
- MTNB 0.07
- VRAX 0.10
- MACD
- MTNB -0.01
- VRAX 0.02
- Stochastic Oscillator
- MTNB 20.07
- VRAX 47.90
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).